Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 23, 2021

Histogen-Amerimmune’s emricasan yields positive results in Covid-19 trial

The drug offered resolution of all symptoms linked to mild Covid-19 and retained it until day 45.

Histogen and its partner Amerimmune have reported top-line data from the Phase I clinical trial where emricasan was found to be safe and well-tolerated in symptomatic patients with mild Covid-19.

A pan-caspase inhibitor, emricasan is intended to lower the enzyme activity associated with inflammation and apoptosis.

The double-blind, randomised, placebo-controlled single-site Phase I trial analysed safety, tolerability and preliminary efficacy of a twice-daily 25mg dose of emricasan in 13 patients in the outpatient setting.

Subjects enrolled at a site in New York City, US received either the treatment or placebo for 14 days and were followed up for a month.

The trial also evaluated several clinical and lab measures and patient-reported outcomes using the US Food and Drug Administration’s (FDA) Covid-19 symptom assessment tool.

According to results from the trial, emricasan was found to be safe and well-tolerated throughout the 14 days of dosing as well as by day 45 of the follow-up period versus placebo.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In addition, no serious adverse events relating to the drug were reported.

Subjects in the emricasan arm experienced a total mild-Covid-19 symptom resolution, including cough, headache, and fatigue by day seven, which continued to day 45.

Histogen noted that subjects receiving placebo did not have a resolution of the disease symptoms until day 45.

Furthermore, improvements were observed in all subjects in the emricasan arm that demonstrated reductions in caspase biomarkers, while those in the placebo arm had symptoms linked to Covid-19 and lab findings.

Histogen president and CEO Richard Pascoe said: “These positive results further reinforce the extensive clinical safety database of emricasan and strongly suggest that emricasan can potentially be developed as a therapeutic treatment for mild to moderate Covid-19, as well as other viral inflammatory diseases.”

In another development, Augmenta Bioworks and TFF Pharmaceuticals have selected monoclonal antibody, AUG-3387, to progress it into the clinic as a potential inhaled therapy for Covid-19 as part of their joint development and partnership agreement.

The companies intend to develop the antibody for Covid-19 patients who are at high risk of developing severe disease but have not been hospitalised yet.

The drug will also be analysed for preventing Covid-19 in people who are at increased risk of developing severe disease.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU